[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"head-and-neck-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:head-and-neck-tumors":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,84,107,135,158,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100552955","phase-1-212pbvmt-alpha-net-in-metastatic-or-inoperable-somatostatin-receptor-positive-gastrointestinal-neuroendocrine-tumors-pheochromocytomaparagangliomas-small-cell-lung-renal-cell-and-head-and-neck-cancers-100552955",false,"NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","* INCLUSION CRITERIA:\n* Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma\u002Fparaganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \\& Neck cancers (nasopharyngeal carcinoma \\[NPC\\], olfactory neuroblastoma \\[ONB\\], sinonasal neuroendocrine carcinoma \\[SNEC\\]) that are metastatic or inoperable per Standard of Care. Note: for KC, all histopathologies of kidney cancers are eligible as long as it is a primary renal neoplasm.\n* Required prior therapies:\n* GI NET, PPGL, H\\&N: no specific prior therapy is needed.\n* SCLC: At least one prior line of standard of care systemic treatment such as chemotherapy and\u002For immunotherapy.\n* KC: Renal cell carcinoma (RCC) participants should have received at least one line of prior therapy in the metastatic setting and should have received at least one Programmed cell death protein 1 (PD1) \u002F Programmed death-ligand 1 (PDL1)-targeted immune checkpoint inhibitor as well as one agent targeting the VEGF pathway. Participants with fumarate hydratase (FH) deficient RCC should have received at least one prior line of systemic therapy (such as bevacizumab plus erlotinib). No prior therapy is needed for participants with other histologic subtypes.\n* Have NOT received prior systemic radioligand therapy for definitive therapeutic purposes. Prior external beam radiation therapy is allowed.\n* History of disease progression by imaging (e.g., RECIST 1.1) or clinically (defined as increase in severity or frequency of symptoms related to disease) within the past 36 months prior to the first dose of \\[203Pb\\]VMT-Alpha-NET.\n* Evidence of somatostatin receptors (SSTR) expression on at least 50% of the radiographically identifiable (i.e., visible on an anatomic scan such as CT or magnetic resonance imaging \\[MRI\\]) tumor, as indicated by a positive (uptake qualitatively identifiable as above the local background) on SSTR PET scan.\n* Age \\>= 18 years.\n* ECOG performance status \\\u003C=1.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Leukocytes: 3,000\u002Fmicroliter\n  * Absolute Neutrophil Count: 1,500\u002Fmicroliter\n  * Platelets 100,000\u002Fmicroliter\n  * Hemoglobin \\>= 9.0 g\u002FdL\n  * Total bilirubin: within normal institutional limits. Note: \\\u003C= 5 X institutional upper limit of normal (ULN) if bilirubin elevation is due to a benign process such as Gilbert syndrome\n  * AST: \\\u003C= 2.5 X institutional ULN\n  * ALT: \\\u003C= 2.5 X institutional ULN\n  * Creatinine: within normal institutional limits\n\nOR\n\n* Calculated creatinine clearance (glomerular filtration rate (eGFR): \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above institutional normal\n\n  * Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression at screening.\n  * Participants with new or progressive brain metastases or leptomeningeal disease are eligible as long as the participant is asymptomatic and not requiring medication for symptom control from the brain lesions at screening.\n  * Participants seropositive for human immunodeficiency virus (HIV) must:\n* be on effective anti-retroviral therapy; and\n* have an undetectable viral load at screening.\n\n  * Participants seropositive for hepatitis B virus (HBV), must have HBV viral load undetectable at screening.\n  * Participants seropositive for hepatitis C virus (HCV) must:\n* received curative treatment; and\n* have an undetectable HCV viral load at screening.\n\n  * Individuals of child-bearing potential (IOCBP) and individuals who can father children must agree to use an effective method of contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) at study entry and up to 6 months after the last dose of the study agent(s).\n  * Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last dose of the study agents.\n  * The ability of the participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Any investigational agents should be stopped at least 28 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET.\n* Systemic therapy should be stopped at least 28 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET (participants with prior systemic therapies for their malignancy only, except participants with SCLC).\n* Systemic therapy should be stopped at least 14 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET (participants with SCLC only).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to VMT-Alpha-NET.\n* Positive Beta human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test performed in IOCBP at screening.\n* QTc \\> 450 ms on electrocardiogram (EKG) at screening. Note: Framingham correction for QTc will be used\n* History of or detection at screening of active\u002Funtreated secondary malignancy except nonmelanoma skin cancer and carcinoma in situ of the uterine cervix.\n* Uncontrolled intercurrent illness, factors, evaluated by medical history and physical exam which would potentially increase in the risk of the participant.","ALL","18 Years","120 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nSome cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that target SSTRs can help shrink these types of tumors.\n\nObjective:\n\nTo test a study drug (\\[212Pb\\]VMT-Alpha-NET) in people with tumors that have SSTRs.\n\nEligibility:\n\nPeople aged 18 years and older with tumors of the lung, kidneys, head and neck, digestive tract, or adrenal glands that have SSTRs. Their tumors must have spread to other organs and cannot be removed with surgery.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and a test of their heart function. A sample of tumor tissue may be collected if one is not already available.\n\n\\[212Pb\\]VMT-Alpha-NET is given through a tube attached to a needle inserted into a vein. The drug will be given on the first day of four 8-week cycles. Participants will stay in the hospital for a few nights after each dose. They will have blood tests once a week during each cycle.\n\nSome participants will also get a related study drug (\\[203Pb\\]VMT-Alpha-NET). They will receive this drug a few days before the first 2 cycles. At 4, 24, and 48 hours after each infusion, they will have whole body scans. These scans will show where the study drug went in their body.\n\nFollow-up visits will continue up to 6 years after the last treatment.",[27,28,29,30,31,32,33,34,35,36],"Sinonasal Neuroendocrine Carcinoma","Nasopharyngeal Carcinoma","Esthesioneuroblastoma","Olfactory Neuroblastoma","Somatostatin Receptor Positive","Small Cell Lung Cancers","Pheochromocytoma\u002FParagangliomas","Kidney Cancers","Head and Neck Tumors","Gastrointestinal Neuroendocrine Tumors",[38,39,40,41],"212Pb","Targeted alpha Therapy","Image-Guided Dosimetry","VMT-alpha-NET","RECRUITING","2026-06-11",{"date":45,"type":46},"2026-06-12","ACTUAL",{"date":48,"type":46},"2025-08-19",{"date":50,"type":21},"2032-01-01",{"name":52,"class":53},"National Cancer Institute (NCI)","NIH",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":54},"100635421","sub-topic-four-clinical-translation-of-original-radioactive-drugs-for-precision-diagnosis-and-treatment-of-gastrointestinal-tumors--clinical-application-value-of-pet-imaging-targeting-lrrc15-in-malignant-tumors-100635421","NCT07552467","Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors","Inclusion Criteria:\n\nEach subject must meet all of the following inclusion criteria to be eligible for study enrollment:\n\n1. The subject or their legally authorized representative (LAR) is capable of providing a signed and dated informed consent form (ICF);\n2. Willing and able to comply with all study procedures and cooperate throughout the entire duration of the study;\n3. Adult patients or healthy volunteers, aged 18 years or older, male or female;\n4. Patients with clinically suspected or confirmed malignancies (supported by evidence such as relevant serum tumor markers, imaging modalities including ultrasound, CT, and MRI, or histopathological examinations) who are in good general condition;\n5. Women of childbearing potential (WOCBP) must have used effective contraception for at least one month prior to screening and agree to continue contraceptive use throughout the study period and for a specified duration following study completion;\n6. Must meet any other protocol-specified inclusion criteria.\n\nExclusion Criteria:\n\nAny subject meeting any of the following baseline criteria will be excluded from the study:\n\n1. Inability to tolerate or complete PET\u002FMR or PET\u002FCT examinations (including, but not limited to, the inability to lie supine, claustrophobia, radiophobia, etc.);\n2. Presence of other comorbidities, such as acute systemic illnesses and electrolyte imbalances;\n3. Known allergy or hypersensitivity to the LRRC15 radiotracer or its synthetic excipients; fasting blood glucose level exceeding 11.0 mmol\u002FL prior to \\[¹⁸F\\]FDG injection;\n4. Patients deemed by the investigator to have poor expected compliance;\n5. Pregnant or lactating (nursing) women;\n6. Presence of any other conditions or factors that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial.",true,{"count":63,"type":21},26,"OBSERVATIONAL","This project utilizes LRRC15-specific targeted PET radiotracers to perform PET\u002FMR or PET\u002FCT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15 expression-including pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumors, glioblastoma, colorectal cancer, and melanoma. The study aims to achieve the following objectives:\n\nFor patients with malignant tumors: To diagnose and stage the disease. By comparing the imaging results against the gold standard of histopathological diagnosis, the study aims to evaluate diagnostic efficacy, ascertain the presence or absence of lesions, and characterize their anatomical location and nature. Furthermore, through comparison with \\[¹⁸F\\]FDG PET or \\[⁶⁸Ga\\]Ga-FAPI PET, the study seeks to achieve accurate disease staging, assess tumor burden, and facilitate therapeutic decision-making.\n\nFor healthy volunteers: To conduct pharmacokinetic analyses to determine the in vivo biodistribution and metabolic patterns of the radiotracer, as well as to evaluate its safety profile.",[67,68,69,70,35,71,72,73],"Pancreatic Cancer","Breast Cancer","Lung Cancer","Sarcoma","Glioblastoma","Colorectal Cancer","Melanoma","2026-04-20",{"date":76,"type":46},"2026-04-27",{"date":78,"type":46},"2026-04-01",{"date":80,"type":21},"2027-03-31",{"name":82,"class":83},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":54},"100490848","multiparametric-imaging-based-intraoperative-navigation-for-guidance-of-surgical-resection-and-postoperative-radiotherapy-in-patients-with-head-and-neck-tumors-100490848","NCT05671458","Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors","Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors - NAVIGATORR","NAVIGATORR","Inclusion Criteria:\n\n* Diagnosis of a malignancy (squamous cell carcinoma (SCC), adenocarcinoma (AC), mucoepidermoid carcinoma (MEC), adenoidcystic carcinoma (ACC)) of the midface, upper jaw and skull-base (e.g. based on imaging-studies and\u002For biopsies)\n* Indication of surgical tumor resection according to multidisciplinary tumor conference\n* Probably indication for postoperative radiotherapy (e.g. T3\u002F4 tumor)\n* Medical operability and written informed consent of the patient to undergo surgical resection (as indicated clinically)\n* Patient age ≥ 18 years\n* Karnofsky performance index ≥ 60%\n* For women with childbearing potential: adequate contraception\n* Ability of subject to understand character and individual consequences of the trial\n* Written informed consent to participate in this trial\n\nExclusion Criteria:\n\n* Contraindications against radiotherapy, especially pregnant or lactating women\n* Refusal of the patient to take part in the study\n* Participation in another competing clinical study or observation period of competing trials",{"count":93,"type":21},60,[95],"NA","The overarching goal of the NAVIGATORR trial is the improvement of local tumor control in head-and-neck cancer (HNC) by increasing the precision of surgical resection and individualization of radiotherapy. Squamous cell carcinomas (SCC) together with salivary gland carcinomas (adenoid cysytic Carcinoma (ACC), mucoepidermoid Carcinoma (MEC), adenocarcinoma (AC)) represent the most common entities in German head and neck oncology. In localized tumors, primary tumor resection with possible adjuvant (chemo)radiotherapy is still the treatment of choice. Advances in targeted therapy and immunotherapy have greatly expanded the repertoire of medical oncology in recent years. In particular, prognosis of patients with end-stage non-small cell lung cancer (NSCLC) has been improved and even patients with advanced head and neck disease can be offered new second line regimes. Importantly, all of these advances are based on personalized and targeted therapies. Unfortunately, surgical oncology in the head-and-neck region has not yet shown such developments towards individualized treatment, so that the rates of safe oncological resections (clear resection margins) haven been stagnating. Despite advances in reconstructive surgery that allow the resection of head-and-neck tumors that would not have been operable 10 - 15 years ago, the basic principles of the resection margin and especially margin evaluation have remained unchanged. The technique of navigation-based tumor resection and the annotation of biopsies by titanium clip-markings or special annotation have been described, but only in small case series and without proving the benefit of the method concerning clinically relevant parameters.\n\nTherefore, the NAVIGATORR trial will enroll 60 patients with HNC of the midface that will undergo navigation-based surgery. Importantly, interdisciplinary data exchange of the intraoperative navigation data between surgeons, pathologists and radiation oncologists will be established. Clear surgical margins (distance between tumor cells and resection border \\> 5 mm) have been defined as primary endpoint. Secondary endpoints such as dosimetric assessment of individualized radiotherapy plans, local tumor control or overall survival should then be compared to data from the literature to further assess this multidisciplinary approach.",[35],"2026-01-08",{"date":100,"type":46},"2026-01-12",{"date":102,"type":46},"2023-01-01",{"date":104,"type":21},"2027-01-01",{"name":106,"class":83},"Juergen Debus",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":54},"100497526","phase-2-tislelizumab-combined-apf-chemotherapy-in-the-treatment-of-locally-advanced-head-and-neck-tumors-100497526","NCT05758389","Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors","A Prospective Single-center, Single-arm Clinical Study of the PD-1 Inhibitor Tislelizumab Combined With APF Sequential Surgery or Radical Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Head and Neck Tumors","Inclusion Criteria:\n\n1. Age 18-75 years old;\n2. Histological or cytology-confirmed head and neck tumors (including oral, oropharynx, hypopharynx, larynx) squamous cell carcinoma, etc.;\n3. Have at least one radiographically measurable lesion (RECIST 1.1 criteria);\n4. The clinical stage is III-IVb (P16-) or II-III (P16+);\n5. There are tumor samples that can detect gene expression;\n6. ECOG score 0-1 points;\n7. Have not received radiotherapy and chemotherapy or other anti-tumor drugs before;\n8. The following hematological indicators need to be met: (1) Neutrophil count≥ 1.5×109\u002FL; (2) Hemoglobin≥ 10g\u002FdL; (3) Platelet count ≥ 100×109\u002FL\n9. The following biochemical indicators need to be met: (1) Total bilirubin ≤1.5× upper limit of normal value (ULN); (2) AST and ALT \\\u003C 1.5 ×ULN; (3) Creatinine clearance ≥ 60ml\u002Fmin; (4) Alkaline phosphatase ≤ 5 times ULN; (5) Activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤1.5xULN (for anticoagulation at a stable dose such as low molecular weight heparin or warfar.) LIN and INR can be screened within the expected therapeutic range of anticoagulants)\n10. Subjects of childbearing age need to take appropriate protective measures (contraceptive measures) before enrollment and in trials administration or other methods of birth control);\n11. Have signed informed consent;\n12. Ability to follow study protocols and follow-up procedures.\n\nExclusion Criteria:\n\n1. Received anti-tumor treatment in the past 6 months, including radiotherapy and chemotherapy, surgery, immunotherapy Wait;\n2. Previously or concurrently suffering from other malignant tumors (except for malignant tumors that have been cured and survived for more than 5 years without cancer, such as skin basal cell carcinoma, cervical carcinoma in situ, superficial bladder cancer, and thyroid papillary carcinoma, etc.);\n3. There is distant metastasis;\n4. Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); but excludes autoimmune-mediated hypothyroidism on stable doses of thyroid replacement hormone; type 1 diabetes on stable doses of insulin; vitiligo or resolved childhood asthma\u002Fallergies, Patients who do not require any intervention after adulthood;\n5. Known history of primary immunodeficiency (including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation);\n6. Severe infection (CTC AE\\>2 grade) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc.; baseline chest imaging examination showed active lung Inflammation, symptoms and signs of infection within 2 weeks before the first use of the study drug or the need for oral or intravenous antibiotic treatment (excluding prophylactic use of antibiotics);\n7. The subject has severe liver and kidney dysfunction, HIV infection, HCV infection, uncontrolled clinical symptoms or diseases of the heart, such as: heart failure above NYHA grade II or echocardiography showing left ventricular ejection fraction (LVEF) \\\u003C 50%; unstable angina; myocardial infarction within 1 year; patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention (including QTc interval ≥ 470 ms); uncontrolled diabetes, uncontrolled Patients with high blood pressure, hypertensive crisis or hypertensive encephalopathy or other diseases considered by the researchers to be ineligible;\n8. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500 IU\u002Fml, or patients with active hepatitis C virus (HCV) should be excluded; inactive hepatitis B surface Antigen carriers, treated and stable hepatitis B patients (HBV DNA\\\u003C500IU\u002Fml), and cured hepatitis C patients can be enrolled;\n9. Have a history of interstitial lung disease (excluding radiation pneumonitis that has not been treated with hormones) and non-infectious pneumonia;\n10. Active tuberculosis infection was found through medical history or CT examination, or patients with a history of active tuberculosis infection within 1 year before enrollment, or patients with a history of active tuberculosis infection more than 1 year ago but without formal treatment;\n11. Patients who have received any of the following treatments (1) Subjects who need to be given corticosteroids (\\> 10 mg prednisone equivalent dose per day) or other immunosuppressants for systemic treatment within 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergies and nausea, Cases of use of corticosteroids for vomiting. In the absence of active autoimmune disease, corticosteroid replacement with inhaled or topical steroids and curative doses of prednisone \\>10 mg\u002Fday is permitted; (2) Have been vaccinated against tumors; those who have been vaccinated or have been vaccinated with live vaccines within 4 weeks before the first administration of the study drug; (3) Received major surgery or severe trauma within 4 weeks before the first use of the study drug; (4) Enrolled in another clinical study at the same time;\n12. Pregnant and lactating women. Women of childbearing age must take a pregnancy test within 7 days before enrollment Negative;\n13. Substance abuse, clinical or psychological or social factors that hinder informed consent or research conduct influences;\n14. Those who may be allergic to the study drug;\n15. Those who cannot perform radiotherapy and chemotherapy due to social or geographical factors;\n16. Significant weight loss within 6 weeks before enrollment (weight loss ≥ 10%);\n17. Any uncertain factors affecting the safety or compliance of the subjects;\n18. Contraindications to hormone use.","75 Years",{"count":116,"type":21},29,[118],"PHASE2","The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are:\n\n1. evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck tumors.\n2. the exploration of efficacy-related immune microenvironment genes Participants will receive tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy.",[35],[122,123,124,125],"Immune checkpoint inhibitors","Chemotherapy","Locally advanced head and neck tumors","Induction therapy","2025-08-29",{"date":128,"type":46},"2025-09-05",{"date":130,"type":46},"2022-04-01",{"date":132,"type":21},"2025-12-07",{"name":134,"class":83},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":142,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":54},"100590523","correlation-and-predictive-research-of-metal-elements-in-radiation-induced-oral-mucositis-100590523","NCT06968520","Correlation and Predictive Research of Metal Elements in Radiation-Induced Oral Mucositis","Correlation and Predictive Study of Metal Elements in Radiation-Induced Oral Mucositis: A Prospective, Longitudinal Cohort Study","Inclusion Criteria:\n\n1）Sign the informed consent form; 2) Confirmed by pathological biopsy as nasopharyngeal carcinoma or head and neck tumors; 3) Have indications for radiotherapy and voluntarily accept radiotherapy; 4) ECOG PS: 0\u002F1; 5) Age: 18-75 years old; 6) Laboratory tests confirm good organ function.\n\nExclusion Criteria:\n\n1. There are contraindications for radiotherapy;\n2. Combined with other tumors;\n3. Pathological sections could not be obtained;\n4. The patient has any serious concurrent diseases that may pose unacceptable risks or have a negative impact on trial compliance. For instance, unstable heart diseases requiring treatment, chronic hepatitis, kidney diseases with poor conditions, uncontrolled diabetes (fasting blood glucose greater than 1.5 × ULN), and mental disorders;\n5. The researcher judged that it was not suitable to participate in this study.",{"count":143,"type":21},383,"Radiotherapy is the main treatment method for head and neck tumors. However, almost all patients with head and neck tumors will develop acute inflammatory reactions such as Radiotherapy-Induced Oral Mucositis (RIOM) after receiving Radiotherapy, resulting in a decline in the quality of life of patients, hindering the smooth implementation of the treatment plan, reducing the therapeutic effect, and increasing the economic burden of patients. However, the current treatment strategies for RIOM focus on symptomatic treatment and have little impact on the course, severity and related complications of mucositis. Therefore, exploring effective strategies, predicting the incidence and severity of RIOM in patients, and providing prevention and treatment are the clinical bottlenecks and cutting-edge issues that urgently need to be solved in the current clinical practice of radiotherapy for head and neck tumors. Previous studies have shown that the steady-state of metallic elements may be closely related to the occurrence and development of RIOM. Therefore, we plan to conduct a prospective, single-center, observational study to further explore the correlation between metal elements and severe RIOM, analyze its predictive efficacy, and observe the dynamic changes of metal elements in radiotherapy.",[35,146,147,148],"Metal","Copper","Radiotherapy-Induced Oral Mucositis","2025-05-05",{"date":151,"type":46},"2025-05-13",{"date":153,"type":46},"2025-04-24",{"date":155,"type":21},"2026-02-28",{"name":157,"class":83},"Nanfang Hospital, Southern Medical University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":166,"studyType":64,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":54},"100576949","study-of-the-contribution-of-mutant-p53yap-proteins-to-therapy-resistance-in-recurrent-head-and-neck-cancer-100576949","NCT06791941","Study of the Contribution of Mutant p53\u002FYAP Proteins to Therapy Resistance in Recurrent Head and Neck Cancer","Inclusion Criteria:\n\n* Age over 18\n* Patients with squamous cell tumors of the oral cavity, pharynx or larynx\n* Surgical patients with primary HNSCC tumors, who have not had previous tumors in other sites or adjuvant treatments prior to surgery.\n* Availability of adequate material (tissue) for the planned analyses\n* Availability of follow-up data for at least one year (retrospective part)\n* Written informed consent (prospective part and\u002For, for the retrospective part, traceable patients and\u002For patients in follow-up and\u002For if necessary for the legal nature\u002Finstitutional purposes of the participating centers).\n\nExclusion Criteria:\n\n* Presence of distant metastases at the time of diagnosis\n* Previous head and neck cancer\n* Second cancer undergoing treatment or follow-up for less than 5 years",{"count":165,"type":21},18,"12 Months","Multicenter, non-interventional, retrospective\u002Fprospective study of a biological nature, on patients affected by head and neck tumors, for which the collection and use of tissue samples is planned for the study of the mutational profile, the transcriptional profile and the proteomic profile.",[35],[170,171,172],"head and neck tumors","TP53","organoids","2025-01-23",{"date":175,"type":46},"2025-01-24",{"date":177,"type":46},"2024-03-07",{"date":179,"type":21},"2029-03-07",{"name":181,"class":83},"Regina Elena Cancer Institute",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":188,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":54},"100575069","breathomics-in-the-diagnosis-and-prediction-of-radiotherapy-induced-oropharyngeal-mucositis-in-head-and-neck-tumors-100575069","NCT06767488","Breathomics in the Diagnosis and Prediction of Radiotherapy-Induced Oropharyngeal Mucositis in Head and Neck Tumors","Inclusion Criteria:\n\n* Voluntarily sign informed consent. Over 18 years of age. Histologically confirmed head and neck tumors, treated with radiotherapy or chemoradiotherapy.\n\nECOG PS Score: 0\u002F1\u002F2.\n\nExclusion Criteria:\n\n* Lung disease such as lung cancer, tuberculosis, and lung infections. Inhalation anesthesia within 3 months. Inhalation medication within 3 months. Postoperative laryngeal cancer. Concurrent serious uncontrolled medical conditions such as unstable heart disease requiring treatment, poorly controlled diabetes mellitus (fasting blood glucose \\> 1.5 x upper limit of normal).\n\nParticipation deemed inappropriate in the judgment of the investigator.",{"count":189,"type":21},375,"Radiotherapy-Induced Oropharyngeal Mucositis (RIOM) is one of the most distressing side effects for patients with head and neck tumors during radiotherapy, requiring clinical physicians to manage it according to the severity of mucositis to alleviate symptoms and improve quality of life. However, traditional diagnosis of RIOM overly relies on subjective evaluation, lacks early sensitivity, and existing biomarker diagnostic methods suffer from insufficient efficacy, invasiveness, and inconsistent results. This study aims to explore the diagnostic and predictive value of exhaled breathomics in RIOM of head and neck tumors. By collecting exhaled breath samples from head and neck tumor patients undergoing radiotherapy and analyzing volatile organic compounds (VOCs) using breath detection technology, we aim to develop and validate a non-invasive diagnostic and predictive model based on exhaled breathomics. The study will identify specific VOCs as potential biomarkers, providing new tools for early diagnosis, timely prediction, and personalized treatment of RIOM.",[35,192,193,194],"Breathomics","Volatile Organic Compounds","Radiotherapy-induced Oral Mucositis","2025-01-08",{"date":197,"type":46},"2025-01-10",{"date":199,"type":46},"2024-12-06",{"date":201,"type":21},"2026-04-30",{"name":157,"class":83}]